Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide + Vorinostat in Pediatric CNS Tumors
NCT03050450Phase 1Terminated
- Sponsor
- Johns Hopkins All Children's Hospital
- Start
- Aug 2016
- Primary completion
- Dec 2018
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lenalidomide and vorinostat in central nervous system tumor (5 arms), sponsored by Johns Hopkins All Children's Hospital. Primary endpoint: Total Number of Adverse Events. Started Aug 2016; status: terminated.
02
Drugs
lenalidomidevorinostat
03
Conditions
central nervous system tumor
Beyond the preview
Go deeper on NCT03050450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03050450.